Gsk (GSK) Restructuring Costs (2009 - 2022)
Gsk (GSK) posted quarterly Restructuring Costs of $465.6 million for Q1 2022, up 191.09% year-over-year from $160.0 million in Q1 2021, and down 42.81% quarter-over-quarter from $814.2 million in Q4 2021.
Gsk (GSK) Restructuring Costs (2009 - 2022) Analysis & Trends
Gsk's Restructuring Costs history runs 9 years deep, the most recent figure standing at $465.6 million for Q1 2022.
- In Q1 2022, Restructuring Costs rose 191.09% year-over-year to $465.6 million; the TTM figure through Mar 2022 stood at $1.9 billion (up 1556.95% YoY), while the FY2015 annual figure was $642.2 million, down 42.26% from the prior year.
- Restructuring Costs for Q1 2022 stood at $465.6 million, down from $814.2 million in the prior quarter.
- The five-year high for Restructuring Costs was $814.2 million in Q4 2021, with the low at $160.0 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 465.62 Mn |
| Dec 31, 2021 | 814.20 Mn |
| Sep 30, 2021 | 399.79 Mn |
| Jun 30, 2021 | 181.70 Mn |
| Mar 31, 2021 | 159.95 Mn |
| Dec 31, 2017 | -205.79 Mn |
| Dec 31, 2016 | -295.89 Mn |
| Dec 31, 2015 | 213.97 Mn |
| Sep 30, 2015 | 66.67 Mn |
| Dec 31, 2014 | 182.21 Mn |
| Mar 31, 2011 | -216.19 Mn |
| Mar 31, 2010 | -469.79 Mn |
| Mar 31, 2009 | -379.36 Mn |